American Medical Association Grants Cardio Diagnostics A Dedicated CPT PLA Reimbursement Code For Epi+Gen CHD, An AI-Powered Test For Assessing The Probability Of A Heart Attack Or Coronary Heart Disease Event
Portfolio Pulse from Benzinga Newsdesk
Cardio Diagnostics Holdings, Inc. (NASDAQ:CDIO) has been granted a dedicated CPT PLA code by the AMA for its AI-powered Epi+Gen CHD test, which assesses the risk of heart attacks or CHD events. This code, effective April 1, 2024, will facilitate reimbursement from federal and private payers, potentially increasing the test's adoption. The Epi+Gen CHD test offers personalized insights into CHD risk, leveraging genetic-epigenetic technology and AI. It has shown to be more sensitive and cost-effective than standard lipid-based risk calculators, especially for women. Cardio Diagnostics also provides an Employer Risk Intelligence platform to help employers manage healthcare costs related to heart disease.
January 03, 2024 | 1:32 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cardio Diagnostics Holdings, Inc. received a CPT PLA code for its Epi+Gen CHD test, which is expected to improve reimbursement processes and increase test adoption. This development could lead to higher revenues and market penetration for CDIO.
The assignment of a dedicated CPT PLA code is a significant milestone for medical tests as it simplifies the billing process and is a key factor in securing reimbursement from insurers. This is likely to increase the adoption of the Epi+Gen CHD test, particularly as it has been shown to be more effective than traditional methods. The news is directly related to Cardio Diagnostics' core product and is expected to have a positive impact on the company's financial performance in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100